Bright Minds Biosciences Participates in Key Scientific Conferences
Bright Minds Biosciences Inc. (CSE: DRUG), a trailblazer in developing selective 5-HT2 agonists, is gearing up for exciting scientific exchanges in the near future. The company is set to showcase its innovative work, focusing on treating drug-resistant epilepsy, depression, and other neurological disorders.
Upcoming Conference Engagements
This biotech firm is scheduled to present its groundbreaking research at several premier scientific conferences:
Neuroscience Annual Meeting
The Neuroscience 2024 meeting, organized by the Society for Neuroscience, will bring together leading experts from October 5–9 in Chicago. Bright Minds will highlight their advancements and novel therapies aimed at addressing critical issues in neurological conditions.
Collaborative Efforts
During the Therapeutic Development event at NINDS on October 7, Bright Minds will discuss their collaborative projects with NIH, focusing on their epilepsy (ETSP) and pain (PSPP) programs. This partnership underscores their commitment to advancing research that bridges clinical and preclinical findings.
BIO-Europe and Chicago Biocapital Summit
In November, Bright Minds will attend BIO-Europe, Europe’s leading partnering event, in Stockholm. This presents a valuable opportunity for networking and fostering relationships with key players in the biotechnology sector. Following this, they will showcase the latest in Midwest biotech at the Chicago Biocapital Summit from November 6-7.
AES Annual Meeting 2024
At the AES Annual Meeting from December 6-10 in Los Angeles, the company will present the efficacy data for BMB-101, their lead compound aimed at treating rare forms of epilepsy. This is a significant moment for the company as it emphasizes their ambitious agenda and ongoing commitment to bringing innovative solutions to market.
Scientific Presentations to Expect
Bright Minds will have several key presentations during these conferences:
Novel 5-HT2A-selective Agonists
Poster Number: PSTR041.28 / N5
Date and Time: October 5, 2024, 1:00 PM - 5:00 PM, MCP Hall A
Phase I Study of BMB-101
Poster Number: 1.532
Date: December 7, South Hall H, Level 1
Innovative Approaches with BMB-101
Poster Number: 1.533
Date: December 7, South Hall H, Level 1
Company Developments: Option Grants
In an exciting move to align interests between the company's success and that of its team, Bright Minds has granted 70,000 options to employees and board members. These options are part of their share option plan, with an exercise price of $1.65 per share, valid for five years. This initiative underscores the company’s strategy to foster commitment and incentivize performance among its workforce.
Highlight on BMB-101
BMB-101 stands out as a promising novel compound specifically designed to tackle chronic neurological disorders. Its unique action as a Gq-protein biased agonist targets the 5-HT2C receptor, a feature that could mitigate the risk of tolerance often affiliated with traditional treatments. The innovative mechanism highlights its potential as a new anti-epileptic drug, ensuring sustained relief for patients who experience difficult-to-manage seizures.
In Phase 1 clinical trials, BMB-101 was administered to 64 healthy volunteers, establishing its safety and tolerability across all doses tested. Remarkably, no severe adverse events were reported, showcasing its profile as a viable candidate for further development. These findings reinforce the company's commitment to finding solutions for patients facing challenging medical conditions.
About Bright Minds Biosciences
Bright Minds Biosciences is dedicated to advancing biomedical solutions for patients suffering from neurological and psychiatric disorders. They focus on developing innovative compounds that target significant receptor pathways to meet the critical medical needs of patients. Through their expansive research and development efforts, they aim to deliver therapies that can lead to transformative changes in the lives of individuals with these challenging conditions.
Contact Information
For more inquiries, reach out to:
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
Phone: (414) 731-6422
Email: alex@brightmindsbio.com
Website: www.brightmindsbio.com
Frequently Asked Questions
What is the focus of Bright Minds Biosciences?
Bright Minds Biosciences specializes in developing selective 5-HT2 agonists for neurological disorders.
What upcoming events is Bright Minds attending?
They will participate in Neuroscience 2024, BIO-Europe, and AES Annual Meeting among others.
What is BMB-101?
BMB-101 is a novel compound aimed at treating drug-resistant epilepsy and related neurological disorders.
How does the company ensure team performance?
Bright Minds grants options to employees to align their interests with company success.
What were the results of the Phase 1 trials for BMB-101?
The trials indicated that BMB-101 is safe and well tolerated by all participants.
